Wyeth’s Desvenlafaxine Advisory Committee Is Cancelled
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA determines that its questions have been satisfactorily answered.
You may also be interested in...
Wyeth To Revisit Launch Plans For Effexor XR Follow-On
The company is waiting for results of lower dose desvenlafaxine studies, but says launch plans are not impacted by FDA's review extension.
Wyeth To Revisit Launch Plans For Effexor XR Follow-On
The company is waiting for results of lower dose desvenlafaxine studies, but says launch plans are not impacted by FDA's review extension.
Schering-Plough Drops Garenoxacin NDA, But Leaves Door Open For Resubmission
Sept. 11 advisory committee meeting on antibiotic cancelled.